Legend Biotech Corp. (LEGN)
15.99
-1.51
(-8.63%)
USD |
NASDAQ |
Nov 16, 16:00
16.10
+0.11
(+0.69%)
After-Hours: 20:00
Legend Biotech Enterprise Value : 2.416B for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 2.416B |
| November 13, 2026 | 2.709B |
| November 12, 2026 | 2.911B |
| November 11, 2026 | 3.105B |
| November 10, 2026 | 3.274B |
| November 09, 2026 | 4.026B |
| November 06, 2026 | 3.854B |
| November 05, 2026 | 3.687B |
| November 04, 2026 | 3.732B |
| November 03, 2026 | 3.481B |
| November 02, 2026 | 3.408B |
| October 30, 2026 | 3.510B |
| October 29, 2026 | 3.640B |
| October 28, 2026 | 3.685B |
| October 27, 2026 | 3.497B |
| October 26, 2026 | 3.270B |
| October 23, 2026 | 3.053B |
| October 22, 2026 | 2.981B |
| October 21, 2026 | 2.929B |
| October 20, 2026 | 3.002B |
| October 19, 2026 | 2.932B |
| October 16, 2026 | 2.899B |
| October 15, 2026 | 3.156B |
| October 14, 2026 | 3.008B |
| October 13, 2026 | 2.783B |
| Date | Value |
|---|---|
| October 12, 2026 | 2.768B |
| October 09, 2026 | 2.927B |
| October 08, 2026 | 2.944B |
| October 07, 2026 | 3.024B |
| October 06, 2026 | 2.946B |
| October 05, 2026 | 2.957B |
| October 02, 2026 | 2.917B |
| October 01, 2026 | 3.062B |
| September 30, 2026 | 3.173B |
| September 29, 2026 | 2.960B |
| September 28, 2026 | 2.922B |
| September 25, 2026 | 3.017B |
| September 24, 2026 | 3.007B |
| September 23, 2026 | 2.889B |
| September 22, 2026 | 2.925B |
| September 21, 2026 | 2.904B |
| September 18, 2026 | 2.726B |
| September 17, 2026 | 2.720B |
| September 16, 2026 | 2.608B |
| September 15, 2026 | 2.737B |
| September 14, 2026 | 2.904B |
| September 11, 2026 | 2.925B |
| September 10, 2026 | 3.032B |
| September 09, 2026 | 3.172B |
| September 08, 2026 | 3.284B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 226.16B |
| Ionis Pharmaceuticals, Inc. | 4.950B |
| Cellectar Biosciences, Inc. | -12.91M |
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 51.84M |
| Revenue (Quarterly) | 360.46M |
| Total Expenses (Quarterly) | 308.62M |
| EPS Diluted (Quarterly) | 0.259 |
| Gross Profit Margin (Quarterly) | 55.88% |
| Profit Margin (Quarterly) | 14.38% |
| Earnings Yield | -0.19% |
| Operating Earnings Yield | 1.24% |
| Normalized Earnings Yield | -0.1182 |